- Gilead Clinical Trials🔍
- Diversity in Clinical Trials🔍
- ClinicalTrials.gov🔍
- Pursuing Advances in Research at Gilead Sciences🔍
- Home Gilead Medical Information🔍
- Designing Inclusive Clinical Trials in an Effort to Upend the HIV ...🔍
- PURPOSE Trials for Lenacapavir🔍
- Gilead Sciences Announces New Clinical Trial in Europe to Assess ...🔍
Gilead Clinical Trials
Gilead Clinical Trials: Creating a Healthier World for All People
“Clinical Trials help us to bring innovative options for new treatments to people living with disease. Our goal is to meet people where they are, understand ...
Diversity in Clinical Trials - Gilead Sciences
We aim to address societal barriers to care that have historically excluded underrepresented and disproportionately impacted communities from taking part in ...
Pursuing Advances in Research at Gilead Sciences
Latest Research Publications · Research-Card-Clinical-Trails-Desktop. Clinical Trials. We're committed to involving the communities most impacted by disease in ...
Home Gilead Medical Information
Explore Additional Gilead Resources · Report Adverse Events · FDA MedWatch · Product Complaints · Gilead Medical Resource Center · Gilead Clinical Study Information ...
Virology, Inflammation, & Oncology Pipeline - Gilead Sciences
Phase 1 clinical trials test an investigational therapy in humans for the first time, with a focus on safety. Participants can be healthy or have been diagnosed ...
Gilead Sciences, a longtime PPD partner, presented an urgent request to initiate global clinical trials of remdesivir, its then-investigational COVID-19 ...
Designing Inclusive Clinical Trials in an Effort to Upend the HIV ...
Gilead's PURPOSE 1 trial focused on African women who have been historically excluded from studies for investigational HIV PrEP therapies.
Home Gilead Medical Information
Gilead Clinical Study Information Center. 1-833-GILEAD-0 (1-833-445-3230) Monday – Friday, 5am – 6pm PT [email protected]. Product Complaints. 1 ...
PURPOSE Trials for Lenacapavir | HIV Prevention
The PURPOSE studies provide new information about HIV prevention through testing a new, twice-yearly injectable medicine, the investigational drug ...
Gilead Sciences Announces New Clinical Trial in Europe to Assess ...
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program · Initiation ...
Gilead Sciences Clinical Trials - GlobalData
GlobalData's premium database of Gilead Sciences Clinical Trials helps in determining Gilead Sciences's go-to-market proposition and gaining insight into ...
Gilead's twice-yearly shot prevents 100% of HIV cases in trial with ...
Gilead's twice-yearly shot prevents 100% of HIV cases in trial with women ... Gilead's share price jumped by 5.7% following the announcement that ...
Clinical Trials and Access - Kite Pharma
© 2017-2024 Gilead Sciences, Inc. All rights reserved. For Kite medical information, clinical trial inquiries, adverse reactions, and product complaints ...
To find out more, read our privacy policy. Accept. Gilead Jobs. Skip to Main Content. gilead Logo. Mobile gilead Logo. What. job title, keywords. Where. city, ...
Gilead Sciences Oncology: New Hope for People with Cancer
Clinical Trials. We're committed to involving the communities most impacted by disease in the design and execution of our clinical trials. Learn More. Our ...
U.S. clinical trials begin for twice-yearly HIV prevention injection
... drug administered by injection every six months. The studies are sponsored and funded by Gilead Sciences, Inc., and implemented through the ...
Gilead ends phase 3 leukemia trial early after data disappoint
In the past two months alone, Gilead has stopped a phase 3 trial in myelodysplastic syndromes (MDS) in the face of lackluster interim efficacy ...
CTI Clinical Trial Servs., Inc. v. Gilead Scis., Inc. - Casetext
Plaintiff CTI Clinical Trial Services, Inc. (CTI) brings this action against defendant Gilead Sciences, Inc. (Gilead) alleging a breach of the parties' ...
Gilead announces new HIV prevention therapy trial in Europe
Gilead Sciences has announced a new clinical study in Europe to evaluate lenacapavir for HIV prevention as part of the Landmark Purpose Program.